We came across a bullish thesis on Soleno Therapeutics, Inc. on X.com by seedy19tron. In this article, we will summarize the bulls’ thesis on SLNO. Soleno Therapeutics, Inc.'s share was trading at $62.74 as of October 8th. SLNO’s forward P/E was 24.15 according to Yahoo Finance.
[caption id="attachment_575379" align="aligncenter" width="750"]Soleno Therapeutics (SLNO) is a single-asset company focused on VYKAT XR, the first and only FDA-approved therapy addressing hyperphagia in Prader-Willi Syndrome (PWS) patients aged four and...
Create a free account, or log in to read the full article
No credit card required.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.